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appearance of skin toxicity and in reducing the number of 
dermal toxicity manifestations in BCP subjected to RT. 
Patient satisfaction was highly positive in the majority of 
cases 
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Purpose/Objective: The purpose of the current clinical trial 
was to evaluate efficiency of palliative external beam 
radiotherapy for symptomatic bone metastases from different 
primary tumors and to search for optimum treatment 
schedules. 
Materials and Methods: The randomized study included 427 
patients treated for 616 sites of bone lesions. Breast was the 
primary site in 67% of cases, prostate - in 7%, lung - in 8%, 
renal - in 6%, other tumors, including sarcomas, melanoma, 
colon cancer and unknown primary site - in 12%. The most 
frequent treatment site was the spine - 48%, followed by 
pelvis - 34%, long bones - 14% and other sites - 4%. The main 
indication for irradiation was pain not alleviated by 
sistematic drug therapy (chemotherapy, target therapy, 
bisphosphonates). Radiotherapy protocol included 
hypofractionation regimes of 2, 3 or 4 fractions of 6,5 Gy 
daily, every two days or every five days and standard 
treatment schedule of 23 fractions of 2 Gy daily. 
Results: The average follow-up period was 41 months. 
General pain relief (complete and partial) was observed in 
95,8% - 100% of sites and was independent of primary tumor, 
metastases localization and irradiation schedules. Complete 
response rate (CRR) was higher for bone metastases from 
breast and prostate cancer 67% and 64% correspondingly in 
comparison with lung and renal cancer - 55% and 33% 
respectively (p<0,05). At small number of observations 
metastases from melanoma and sarcomas proved high 
radiosensitivity with CRR 75% and 69% correspondingly. CRR 
for spine and pelvis localization of metastases was similar - 
63,4% and 59,3%, slightly lower for long bones - 48,3% and 
significantly lower for sacrum isolated metastases - 27% 
(p<0,05). CRR significantly increased from 43,6% to 47,9% and 
64,4% for 2, 3 and 4 fractions of 6,5 Gy correspondingly 
(p<0,03). The pain relapse rate in irradiated zone was 8,2% 
and detected no correlation with histology type, metastatic 
site, dose and fractionation schedules. The acute toxicity 
rate (RTOG/EORTC) comprised 24-32% independently of 
irradiation regimes. Late radiation morbidity was observed in 
15,7% for standard treatment schedule and decreased in 
consecutive way for 4, 3 and 2 fractions of 6,5 Gy (14,4%, 
10,9% and 8,3% respectively). Late toxicity grade 2 was 
significantly lower (1,7%, p<0,05) for 3 fractions regime. 
Conclusions: Histogenesis of primary tumor is a predictor of 
radiosensitivity of bone metastases, it significantly affects 
the complete pain response rate. It is expedient to use 
hypofractionation regimes of 3 fractions of 6,5 Gy (total dose 
19,5 Gy) for palliative radiotherapy for bone metastases in 
case of breast and prostate cancer and 4 fractions of 6,5 Gy 
(total dose 26 Gy) in case of lung and renal cancer daily, 
every two days or every five days. In the multifactorial 
analysis tumor primary site and pain intensity before 
radiotherapy were the only independent prognostic factors of 
CRR.  
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Purpose/Objective: The assessment of response to 
radioembolization (RE) of liver metastases is difficult because 
the effect of the radiation on tumour burden is quite 
different from those of chemotherapeutic agents, and 
patients undergo this treatment after multiple systemic and 
regional therapies which determine dramatic changes in liver 
density - caused by necrosis or sclerosis. 18F-FDG-PET/CT has 
been documented as a powerful tool in this respect, 
nonetheless there is not agreement about the optimal 
imaging choice (CT vs. FDG-PET/CT). We investigated the 
accuracy of different parameters derived from CT and 18F-
FDG PET/CT in early predicting the outcome after RE 
Materials and Methods: Patients with chemo-refractory liver 
metastases from solid tumours scheduled to receive RE 
underwent 18F-FDG-PET/CT and CT scan before and 6 weeks 
after RE. Response to treatment was assessed in PET 
according to PERCIST criteria, and metabolic tumour volume 
(MTV), in CT according to RECIST criteria. Overall survival 
(OS) rates were calculated using the Kaplan Meyer method, 
and differences among scoring criteria were explored with 
the log-rank test 
Results: 22 patients were suitable for analysis. All patients 
received a single treatment of RE, with a median activity of 
1.7 GBq (range 0.6-2.9) of 90Y microspheres. Metabolic 
response correlated significantly with OS. For PERCIST, the 
median OS was 28.4 months (95 % CI, 12.4–44.4 mo) in 
patients with CR, 17.7 mo (5.0–30.5 mo) in patients with PR 
and 4.8 mo (2.9–6.8 mo) in those who had SD (see Figure 1). 
All these differences were statistically significant (p<0.05). 
Moreover, responders (CR+PR) had a median OS of 20.6 mo 
(5.7–35.5 mo) with a significant longer OS compared to those 
who showed SD. 
MTV did not produce the expected results, i.e. did not 
correlate with the survival. In several patients we 
experienced some difficulty in defining lesion margins and 
establishing a threshold vs the surrounding liver parenchyma. 
Concerning RECIST criteria, there was no straight separation 
between patients who responded to RE and those who did 
not. The median OS for patients with PR, SD and PD was 20.6 
(14.5-32.8 months), 11.8 (7.9-29.6 months), and 2.7 months 
(0-15.5 months), respectively. Despite the median response 
values were separated, the statistical analysis of the survival 
curves did not reveal any significant difference among the 
four scores (CR, PR, SD, PD).  
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The amount of liver involved in the disease was not 
associated with the outcome 
Conclusions: FDG-PET/CT was able to separate responders 
from non-responders about 6 weeks after RE when using 
PERCIST criteria.  
Although MTV may provide a baseline prognostic factor, in 
our experience, the MTV obtained from a manual contouring 
resulted to be inappropriate to predict the therapeutic 
response. More sophisticated segmentation methods should 
be analysed to assess the MTV usefulness. 
Overall, contrarily to CT, FDG-PET/CT about 6 weeks after 
the treatment can provide early response and survival 
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Purpose/Objective: SBRT for liver metastases has shown in 
many reports a high rates of Local Control (LC), mild toxicity, 
and a positive trend on overall survival (OS).However, many 
questions about the prognostic factors that can influence LC 
and OS are still open. In this study we analyzed our cohort of 
patients treated for CRC liver metastases by SBRT. 
Materials and Methods: Between April 2006 and February 
2014, 89 pts with 163 colorectal metastases were treated by 
SBRT. Median age was 65 ys ,with KPS >70. 45% of them had 
synchronous mets and in 79% a primary tumor was controlled, 
47 patient (52%) were treated to a single lesion and 48% pts 
to two to five mets. 85% of pts received previous 
chemotherapy. SBRT was delivered by 6MV Linac using beam 
modulator (VMAT). Median GTV volume was 20 cc (0.3-306 
cc). Dose delivered in 3 fx was prescribed to the 67% isodose 
line in 82% of lesions and to the isocenter in 17%. In 81.5 % of 
lesions the relative BED 10 was > 100 Gy. Dose constraint for 
healty liver was D700 mL< 15 Gy . Set-up and isocenter position 
was controlled before each fx using CBCT, gold markers as 
target surrogate were implanted in 78 % of pts. Respiratory 
motion was controlled by active breathing coordinator, 
breath hold technique or delineating an ITV of inhale an 
exhale CT data in 62%, 30% and 8% respectively. The response 
was evaluated 60 days after SBRT by CT and PET scan and 
every 3monyhs successively. Toxicity was assessed by CTCAE 
score. 
Results: With a median FU of 16.5 (range 5-75) months, the 
median survival was 44.4 months. 23 Pts are still alive(26%). 
LC, defined as no evidence of tumor regrowth within the 
treated lesion, was reached in 84% of lesions. Mainly relapses 
occurred outside the treated field : in 23% (21/89) of pts the 
'in field' relapses occurred in the presence of 'out of field' 
progression while single only patient relapsed in field only. 
47 (53%) through the liver and 49 (55%)outside.1 y and 2 ys LC 
was respectively 83% and 69%. On univariate analysis, better 
LC was statistically related to the use of Gold Fiducials (p< 
0,001), Breath Control (p=0.013), BED 10 >100Gy (p< 0,001) 
and prescription to 67% isodose vs isocenter (p <0,001), GTV 
volume < 14 cc (p= 0.029) . 1y and 2 ys OS were 75% and 33% 
respectively. The OS rate seems not to be related to age, the 
number of liver lesions at diagnosis, mets Synchronous, use of 
chemotherapy while better OS was related to single lesions vs 
more than one treated (p= 0.041) by SBRT. Furthermore 
improved OS was associated with no relapse through the 
liver, 1y and 2 ys OS was 88% and 45% respectively for no 
recurrence vs 64% and 23% for hepatic relapse 
(p=0.005).Acute toxicity was only gastrointestinal in 11% of 
Pts G1 and in 4% G2.  
 
Conclusions: In our experience SBRT for CRC liver mets is a 
safe and an effective ablative therapy that could be offered 
to patients not suitable to others therapies. Disease 
progression occurs mainly outside the treated field. Probably, 
limiting our sample of pts to the oligometastatic subset 
would have a greater impact on OS rates. 
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Purpose/Objective: Head and neck cancer (HNC) is the most 
common cancer in developing countries. Pain is the 
commonest symptom in HNC patients and it may be due to 
the tumour and/or cancer treatment. Previous studies have 
shown these patients to be at risk for inadequate pain 
management. This study evaluates pain and the adequacy of 
analgesic management during radiation. 
Materials and Methods: 60 patients of locally advanced head 
and neck cancers treated primarily with conventional chemo-
radiation or adjuvant radiation +/- concomitant 
chemotherapy following surgery (60-66 Gy / 30-33 # / 6 – 6.5 
weeks) were included in the study. Patients completed the 
Brief Pain Inventory (BPI) Questionnaire at time of initial 
visit, 3 weeks of CCRT/RT, at the end of treatment and at 3 
months of follow-up. Pain intensity scores were derived from 
the BPI Questionnare. 
Pain intensity scores were: 1-3 – Mild, 4-7 – Moderate, 8-10 – 
Severe. Analgesics prescribed were derived from WHO's 
'Analgesic Ladder' approach to cancer pain. Analgesic scores 
were: NSAIDS and Adjuvants – 1, Mild opioids – 2, Strong 
opioids – 3.  
The Pain Management Index (PMI) is a simple index linking 
the usual severity of cancer pain with the category of 
